当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.

Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.

Abstract：

OBJECTIVE:Most women with ovarian cancer relapse and undergo further chemotherapy however evidence regarding the benefits of this for women with platinum-resistant disease is limited. Our objective was to determine whether there was a quality of life improvement or treatment response among women treated for platinum-resistant recurrent ovarian cancer. METHODS:We combined data from 2 studies where women treated with chemotherapy for recurrent ovarian cancer (n=172) completed a quality of life questionnaire every 3 months. Cancers were classified as platinum-resistant if they progressed within 6 months of completing first-line chemotherapy. Mixed effects models were used to analyze change in quality of life during the first 6 months after second-line chemotherapy. RESULTS:One-quarter of women (n=44) were classified as having platinum-resistant disease. Overall, their quality of life did not significantly increase or decrease, following commencement of second-line chemotherapy (least square mean scores=107, 105, 103 at chemotherapy start, 3 and 6 months later, respectively), although 26% of these women reported a meaningful increase and 31% reported a meaningful decline. One-third of the platinum-resistant group responded (11% complete and 21% partial response) to second-line chemotherapy, and this figure increased to 54% among the subset (36%) re-treated with platinum-based agents with or without other agents. Preliminary analyses suggest that quality of life may be higher at chemotherapy initiation in women whose disease responded (median score 121 vs 110). CONCLUSIONS:Overall, quality of life appears to be maintained in women with platinum-resistant ovarian cancer who receive further chemotherapy and some women respond to re-treatment.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Beesley VL,Green AC,Wyld DK,O'Rourke P,Wockner LF,deFazio A,Butow PN,Price MA,Horwood KR,Clavarino AM,Australian Ovarian Cancer Study Group,Australian Ovarian Cancer Study-Quality Of Life Study Investigators,Webb PM

doi

10.1016/j.ygyno.2013.10.004

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

130-6

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(13)01248-1

journal_volume

132

pub_type

杂志文章

相关文献

GYNECOLOGIC ONCOLOGY文献大全
  • Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.

    abstract：:Pretreatment serum levels of the tumor-associated antigens CA-125, tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA), and placental alkaline phosphatase (PLAP) were analyzed in 142 patients with epithelial ovarian carcinoma, and related to clinical and histopathological parameters. In a linear multiple ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(90)90394-z

    authors： Tholander B,Taube A,Lindgren A,Sjöberg O,Stendahl U,Tamsen L

    更新日期：1990-10-01 00:00:00

  • Enhanced radiosensitization with interferon-alpha-2b and cisplatin in the treatment of locally advanced cervical carcinoma.

    abstract：PURPOSE:To evaluate the efficacy and toxicity of interferon-alpha-2b (IFN-alpha) and cisplatin given concomitantly with radiation therapy (RT) in the treatment of locally advanced cervical carcinoma. MATERIALS AND METHODS:Twenty-one patients with stage bulky Ib-IIIb (Ib, 2; IIa, 2; IIb, 8; IIIb, 9) cervical carcinoma ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1997.4879

    authors： Stock RG,Dottino P,Jennings TS,Terk M,DeWyngaert JK,Beddoe AM,Cohen C

    更新日期：1997-12-01 00:00:00

  • Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.

    abstract：OBJECTIVE:For many years, BRCA mutational status has only been considered as a predictor of ovarian cancer susceptibility and as a prognostic factor. Nonetheless, in the era of precision medicine, it has also become a predictive biomarker of response to platinum-based-chemotherapy and, more recently, to PARP-inhibitors...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2020.06.479

    authors： Marchetti C,Minucci A,D'Indinosante M,Ergasti R,Arcieri M,Capoluongo ED,Pietragalla A,Caricato C,Scambia G,Fagotti A

    更新日期：2020-09-01 00:00:00

  • Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer.

    abstract：OBJECTIVE:The aim of this study is to evaluate the efficacy of intraperitoneal cisplatin as consolidation treatment in epithelian ovarian cancer patients with complete pathologic response following front-line platin-based chemotherapy. PATIENTS AND METHODS:Thirty patients who had no evidence of disease as assessed by ...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.ygyno.2003.10.002

    authors： Topuz E,Eralp Y,Saglam S,Saip P,Aydiner A,Berkman S,Yavuz E

    更新日期：2004-01-01 00:00:00

  • Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group.

    abstract：OBJECTIVE:We assessed the antineoplastic effect and adverse reactions of paclitaxel monotherapy with paclitaxel 210 mg/m(2) given every 3 weeks by 3-h infusion on patients with endometrial cancer given as a 3-h infusion. METHODS:This study was a multi-center, open-label phase II clinical trial of paclitaxel 210 mg/m(2...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.ygyno.2004.05.042

    authors： Hirai Y,Hasumi K,Onose R,Kuramoto H,Kuzuya K,Hatae M,Ochiai K,Nozawa S,Noda K

    更新日期：2004-08-01 00:00:00

  • Detection of beta-subunit human chorionic gonadotropin mRNA in the peripheral blood of patients with nonmetastatic gestational trophoblastic disease.

    abstract：OBJECTIVE:The aim of this study was to detect beta-subunit human chorionic gonadotropin (beta(h)CG) mRNA in the peripheral blood samples of patients with nonmetastatic gestational trophoblastic disease (GTD) undergoing hysterectomy. METHODS:Heparinized peripheral blood samples were obtained from four patients with non...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2002.6716

    authors： Suzuka K,Matsui H,Iitsuka Y,Sekiya S

    更新日期：2002-07-01 00:00:00

  • PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.

    abstract：OBJECTIVES:To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients with recurrent or metastatic cervical cancer. To determine the association between histology and programmed death-ligand 1 (PD-L1) expres...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2020.08.026

    authors： Rischin D,Gil-Martin M,González-Martin A,Braña I,Hou JY,Cho D,Falchook GS,Formenti S,Jabbour S,Moore K,Naing A,Papadopoulos KP,Baranda J,Fury W,Feng M,Stankevich E,Li J,Yama-Dang NA,Yoo SY,Lowy I,Mathias M,Fury

    更新日期：2020-11-01 00:00:00

  • Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.

    abstract：PURPOSE:Five recent phase III trials provide strong evidence that a new alternative therapy, cisplatin-based chemoradiation, is more effective than standard therapy using radiation alone in the treatment of advanced cervical cancer. We conducted a pharmacoeconomic analysis to determine whether the alternative cisplatin...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1006/gyno.2000.5810

    authors： Rose PG,Lappas PT

    更新日期：2000-07-01 00:00:00

  • Cloacogenic adenocarcinoma of the vulva.

    abstract：:Primary adenocarcinoma of the vulva is rare, and cloagocenic adenocarcinoma of the vulva is extremely rare. Here we report a vulvar tumor characterized by columnar cells with prominent brush border and the presence of goblet cells and endocrine cells, presenting the tubulovillous pattern and mucin histochemistry of en...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1999.5433

    authors： Willén R,Békássy,Carlén B,Bozoky B,Cajander S

    更新日期：1999-08-01 00:00:00

  • Sentinel lymph node biopsy in the management of early-stage cervical carcinoma.

    abstract：OBJECTIVES:We aimed to determine the sentinel lymph node detection rates, accuracy in predicting the status of lymph node metastasis, and if pathologic ultrastaging improves the detection of micrometastases and isolated tumor cells at the time of primary surgery for cervical cancer. METHODS:A prospective, non-randomiz...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2010.12.334

    authors： Diaz JP,Gemignani ML,Pandit-Taskar N,Park KJ,Murray MP,Chi DS,Sonoda Y,Barakat RR,Abu-Rustum NR

    更新日期：2011-03-01 00:00:00

  • Specialist surgery for ovarian cancer in England.

    abstract：OBJECTIVE:The aim of this study is to evaluate the impact of the 1999 national recommendations for ovarian cancer surgery in England to be performed by specialist surgeons in specialist centres. METHODS:A retrospective analysis of English cancer registry records, Hospital Episode Statistics (HES) data for all English ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2015.03.003

    authors： Butler J,Gildea C,Poole J,Meechan D,Nordin A

    更新日期：2015-09-01 00:00:00

  • CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors.

    abstract：OBJECTIVE:Three founder alleles of the CHEK2 gene have been associated with predisposition to a range of cancer types in Poland. Two founder alleles (1100delC and IVS2 + 1G >A) result in a truncated CHEK2 protein and the other is a missense substitution, leading to the replacement of a threonine with an isoleucine (I15...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2006.05.040

    authors： Szymanska-Pasternak J,Szymanska A,Medrek K,Imyanitov EN,Cybulski C,Gorski B,Magnowski P,Dziuba I,Gugala K,Debniak B,Gozdz S,Sokolenko AP,Krylova NY,Lobeiko OS,Narod SA,Lubinski J

    更新日期：2006-09-01 00:00:00

  • Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen.

    abstract：OBJECTIVES:Sonohysterography (SHG) has been proposed as a useful tool for the surveillance of the endometrium in patients receiving tamoxifen. This study aimed to assess the value of SHG in asymptomatic patients who would have been biopsy candidates because of abnormal transvaginal ultrasound (TVUS) results. METHODS:T...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1006/gyno.2000.5876

    authors： Bertelli G,Valenzano M,Costantini S,Rissone R,Angiolini C,Signorini A,Gustavino C

    更新日期：2000-09-01 00:00:00

  • Management of early ovarian cancer: germ cell and sex cord-stromal tumors.

    abstract：:Malignant ovarian germ cell tumors (OGCT) and sex cord-stromal tumors (OSCST), each of which account for less than 5% of all ovarian malignancies, are much less common than epithelial ovarian cancer. In young patients suspected of having an OGCT, laparotomy is initially indicated for both diagnosis and treatment. For ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：

    authors： Gershenson DM

    更新日期：1994-12-01 00:00:00

  • Implementation of a standardized voiding management protocol to reduce unnecessary re-catheterization - A quality improvement project.

    abstract：OBJECTIVE:To design and implement a standardized postoperative voiding management protocol that accurately identifies patients with urinary retention and reduces unnecessary re-catheterization. METHODS:A postoperative voiding management protocol was designed and implemented in patients undergoing major, inpatient, non...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2020.01.036

    authors： Brackmann M,Carballo E,Uppal S,Torski J,Reynolds RK,McLean K

    更新日期：2020-05-01 00:00:00

  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?

    abstract：OBJECTIVES:Lymphovascular space invasion (LVSI) is an independent risk factor for recurrence and poor survival in early-stage endometrioid endometrial cancer (EEC), but optimal adjuvant treatment is unknown. We aimed to compare the survival of women with early-stage EEC with LVSI treated postoperatively with observatio...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2019.12.028

    authors： Beavis AL,Yen TT,Stone RL,Wethington SL,Carr C,Son J,Chambers L,Michener CM,Ricci S,Burkett WC,Richardson DL,Staley AS,Ahn S,Gehrig PA,Torres D,Dowdy SC,Sullivan MW,Modesitt SC,Watson C,Veade A,Ehrisman J,Havril

    更新日期：2020-03-01 00:00:00

  • Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.

    abstract：OBJECTIVE:Heredity is a major cause of ovarian cancer and during recent years the contribution from germline mismatch repair (MMR) gene mutations linked to Lynch syndrome has gradually been recognized. METHODS:We characterized clinical features, tumor morphology and mismatch repair defects in all ovarian cancers ident...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.02.010

    authors： Ketabi Z,Bartuma K,Bernstein I,Malander S,Grönberg H,Björck E,Holck S,Nilbert M

    更新日期：2011-06-01 00:00:00

  • Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.

    abstract：OBJECTIVE:This study aimed to evaluate the prognostic value of quantitative metabolic parameters measured on F-18 FDG PET/CT (FDG PET/CT) at the time of the first relapse in patients with relapsed epithelial ovarian cancer (EOC). METHODS:Fifty-six relapsed EOC patients were retrospectively included. Quantitative metab...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2014.12.032

    authors： Kim CY,Jeong SY,Chong GO,Son SH,Jung JH,Kim DH,Lee SW,Ahn BC,Lee J

    更新日期：2015-03-01 00:00:00

  • The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts.

    abstract：OBJECTIVE:To examine the influence of diabetes and metformin therapy on overall survival (OS) and progression-free survival (PFS) in patients with endometrial cancer (EC) by using propensity score (PS) matching to account for confounding factors. METHODS:We retrospectively identified consecutive patients with stage I-...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2015.11.019

    authors： Al Hilli MM,Bakkum-Gamez JN,Mariani A,Cliby WA,Mc Gree ME,Weaver AL,Dowdy SC,Podratz KC

    更新日期：2016-02-01 00:00:00

  • Surgical approach to diaphragmatic metastases from ovarian cancer.

    abstract：:Fourteen patients underwent surgical debulking of diaphragmatic metastases as part of cytoreductive surgery for advanced ovarian epithelial cancer from 1983 to 1984. The surgical technique is described. Morbidity from this approach was not excessive in this small series of patients. It is suggested that this technique...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(86)90034-x

    authors： Deppe G,Malviya VK,Boike G,Hampton A

    更新日期：1986-06-01 00:00:00

  • Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace.

    abstract：:A 46-year-old women presented with an inoperable low-grade endometrial stromal sarcoma. Two doses of Depo-Lupron, 7.5 mg, and Megace, 160 mg/day, were given to control uterine bleeding and shrink the tumor mass. In 9 weeks, significant reduction in the tumor occurred allowing for surgical resection. Total abdominal hy...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1998.5174

    authors： Scribner DR Jr,Walker JL

    更新日期：1998-12-01 00:00:00

  • Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity.

    abstract：OBJECTIVE:The objective of this study was to evaluate the risk factors and potential morbidity associated with intraoperative hypothermia (IH) during cytoreductive surgery (CRS) for advanced ovarian cancer. METHODS:Demographic and perioperative data were collected for all patients with stage IIIC-IV ovarian, fallopian...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.08.034

    authors： Long KC,Tanner EJ,Frey M,Leitao MM Jr,Levine DA,Gardner GJ,Sonoda Y,Abu-Rustum NR,Barakat RR,Chi DS

    更新日期：2013-12-01 00:00:00

  • Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

    abstract：OBJECTIVE:Doxorubicin has reported activity in advanced and recurrent cervical cancer but hematologic toxicity has limited its use in some combinations. To determine the level of activity and potential for use in future combinations, a phase II trial of pegylated liposomal doxorubicin as second-line therapy in advanced...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2005.11.048

    authors： Rose PG,Blessing JA,Lele S,Abulafia O

    更新日期：2006-08-01 00:00:00

  • Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity.

    abstract：:Recombinant human tumor necrosis factor (rHuTNF) is a macrophage-secretory protein with antitumor activity. In vivo and in vitro cytotoxicity studies have been carried out to test the effectiveness of rHuTNF alone or in combination with chemotherapeutic agents. We have evaluated the direct cytotoxic effect of rHuTNF o...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(91)90254-3

    authors： Vigani A,Chiara S,Miglietta L,Repetto L,Conte PF,Cimoli G,Morelli L,Billi G,Parodi S,Russo P

    更新日期：1991-04-01 00:00:00

  • DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.

    abstract：OBJECTIVE:The present study was undertaken to analyze the impact of epigenetic alterations with a main focus on nuclear area, aneuploidy, hyperploidy, and proliferation in 70 ovarian cancer specimens. METHODS:Morphometric changes and somatic chromosomal ploidy status were assessed by Feulgen spectrophotometry. DNA-hyp...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2010.12.332

    authors： Zeimet AG,Fiegl H,Goebel G,Kopp F,Allasia C,Reimer D,Steppan I,Mueller-Holzner E,Ehrlich M,Marth C

    更新日期：2011-04-01 00:00:00

  • Clinical audit in gynecological cancer surgery: development of a risk scoring system to predict adverse events.

    abstract：BACKGROUND:Advanced gynecological surgery undertaken in a specialized gynecologic oncology unit may be associated with significant perioperative morbidity. Validated risk prediction models are available for general surgical specialties but currently not for gynecological cancer surgery. OBJECTIVE:The objective of this...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2009.08.004

    authors： Kondalsamy-Chennakesavan S,Bouman C,De Jong S,Sanday K,Nicklin J,Land R,Obermair A

    更新日期：2009-12-01 00:00:00

  • Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.

    abstract：OBJECTIVE:Our aim was to characterize the pathological, molecular and clinical outcomes of clear cell carcinoma of the endometrium (CCC). METHODS:CCC underwent ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) classification identifying four molecular subtypes: i) 'POLEmut' for ECs with pathogenic P...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2020.04.043

    authors： Kim SR,Cloutier BT,Leung S,Cochrane D,Britton H,Pina A,Storness-Bliss C,Farnell D,Huang L,Shum K,Lum A,Senz J,Lee CH,Gilks CB,Hoang L,McAlpine JN

    更新日期：2020-07-01 00:00:00

  • Simple extrafascial trachelectomy and pelvic bilateral lymphadenectomy in early stage cervical cancer.

    abstract：OBJECTIVE:To determine the feasibility and safety of simple extra-fascial trachelectomy plus pelvic lymphadenectomy in young patients affected by early stage cervical cancer. METHODS:We have prospectively identified all patients with early-stage cervical cancer (stages IA2-IB1) referred to our department. Inclusion cr...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.ygyno.2012.04.004

    authors： Palaia I,Musella A,Bellati F,Marchetti C,Di Donato V,Perniola G,Benedetti Panici P

    更新日期：2012-07-01 00:00:00

  • Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?

    abstract：OBJECTIVE:To determine whether intra-operative radiation therapy (IORT) at the time of pelvic exenteration (PE) or laterally extended endopelvic resection (LEER) improves progression-free survival (PFS) in patients with recurrent, previously irradiated gynecologic cancers. METHODS:We conducted a single institution ret...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2014.07.093

    authors： Backes FJ,Billingsley CC,Martin DD,Tierney BJ,Eisenhauer EL,Cohn DE,O'Malley DM,Salani R,Copeland LJ,Fowler JM

    更新日期：2014-10-01 00:00:00

  • High external parametrial dose can increase the probability of radiation proctitis in patients with uterine cervix cancer.

    abstract：OBJECTIVE:The aim of this study was to evaluate the relationship between external parametrial dose and radiation proctitis after external irradiation and high-dose-rate intracavitary (HDR-IC) brachytherapy among patients with cervical cancer. METHODS:From May 1993 through December 1996, 191 patients with stage IB-IVA ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2000.5997

    authors： Huang EY,Lin H,Hsu HC,Wang CJ,Chen HC,Sun LM,Hsiung CY

    更新日期：2000-12-01 00:00:00